We recently finished a live case treating Barrett's esophagus: Impressive treatment performed by Dr. Vinay Sehgal using PENTAX Medical C2 CryoBalloon™ ablation. As nicely demonstrated, it is a safe and effective procedure, and it is easy to use by both the physician and the staff. As shown, it can effectively eradicate esophageal dysplasia and metaplasia, ultimately reducing the risk of developing esophageal cancer*. #PENTAXMedical #CryoBalloon #Innovation * Reference: 1) Frederiks C. N., et al., Comparison of focal cryoballoon ablation with 10- and 8-second
PENTAX Medical Americas’ Post
More Relevant Posts
-
We recently finished a live case treating Barrett's esophagus: Impressive treatment performed by Dr. Vinay Sehgal using PENTAX Medical C2 CryoBalloon™ ablation. As nicely demonstrated, it is a safe and effective procedure, and it is easy to use by both the physician and the staff. As shown, it can effectively eradicate esophageal dysplasia and metaplasia, ultimately reducing the risk of developing esophageal cancer*. #PENTAXMedical #CryoBalloon #Innovation * Reference: 1) Frederiks C. N., et al., Comparison of focal cryoballoon ablation with 10- and 8-second
-
-
We recently finished a live case treating Barrett's esophagus: Impressive treatment performed by Dr. Vinay Sehgal using PENTAX Medical C2 CryoBalloon™ ablation. As nicely demonstrated, it is a safe and effective procedure, and it is easy to use by both the physician and the staff. As shown, it can effectively eradicate esophageal dysplasia and metaplasia, ultimately reducing the risk of developing esophageal cancer*. #PENTAXMedical #CryoBalloon #Innovation * Reference: 1) Frederiks C. N., et al., Comparison of focal cryoballoon ablation with 10- and 8-second
-
-
Poster 2 of 3 Hemant Rathi would be presenting our research titled: “Real-World Effectiveness and Safety of First-Line Pembrolizumab Monotherapy for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis” at #ISPORAnnual Co- authors: Geetank Kamboj, Aastha Radotra, PARINITA BARMAN, Shirish Dongare, PhD, Surabhi Aggarwal, Hemant Rathi #ISPOR2024 #HEOR #SkywardAnalytics #LiteratureReviews #SLR #MetaAnalysis
-
-
Chief Medical Officer at CLEARA Biotech BV, leading clinical development, translational science and medical affairs in oncology projects
Very interesting newly disclosed clinical efficacy data in 3L NSCLC with MAIA Biotechnology, Inc.'s flagship pipeline agent THIO administered in combination with a checkpoint inhibitor. This is a profoundly challenging clinical scenario, characterized by 'slim pickings' re agents that could accord meaningful benefit to suffering patients, thus representing an unmet medical need for the majority of NSCLC patients whose disease progresses after failure of 2nd line therapies. THIO's dual mechanism of action is novel and intriguing, as the drug is designed to induce telomeric DNA damage and boost cancer-specific immune responses (thus synergizing with concomitantly administered CPIs). Certainly, an evolving 'story' worth following closely, as it could potentially differentiate THIO in a strong manner against a 'crowded' IO therapy landscape. Kudos to the company's CEO, Vlad Vitoc, MD, MBA, and all the teams supporting THIO's discovery and clinical development!
#ICYMI: MAIA recently released key achievements year-to-date, including #clinical progress for lead candidate THIO, a potential first-in-class cancer telomere targeting agent in clinical development, to evaluate its activity in #NSCLC. Read more: https://bit.ly/4bNqiy7
-
-
🆕#IARCpaper in The Lancet aims to evaluate which #HPV genotypes caused #CervicalCancer, as well as their carcinogenic strength and contribution to burden of #CxCa. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature: https://lnkd.in/dAGfNnYy
-
-
A single piece of dried blood could be all that is needed for a new AI-powered test that can swiftly and effectively identify three main forms of cancer one day. In early trials, the instrument demonstrated the ability to discriminate between those without cancer and those with confirmed pancreatic, gastric, or colorectal cancer and the analytic process took only a few minutes, according to Live Science. #AI #artificialintelligence #NewsUpdate #pakstream #pakistan
-
-
❗️Drs. Suneel Kamath, Arvind Dasari, and Sakti Chakrabarti discuss the management of oligometastatic #colorectal cancer in a roundtable moderated by Dr. Shikha Jain: https://buff.ly/4eNZ9No 👉 The panel emphasizes the importance of a multidisciplinary approach, local therapies, and tailored treatments.
-
Our abstract has been accepted by #EAU24 in Paris! 'A new approach to data integration with Al to enhance the specificity of prostate cancer diagnosis' will be presented by Prof Nikhil Vasdev. Join this session on 7 April! #EAU2024
-
-
👉 Patients expect more research to be done for neuroendocrine cancer. NET clinical trials are the way to advance treatments and consider quality of life of patients on their journey. ✔ Get a snapshot of the global map of NET clinical trials with this innovative trial finder that will consider the specifics of your condition and your location: https://lnkd.in/dABv_heE Ancora.ai NORCAL CARCINET SUPPORT GROUP #LetsTalkAboutNETs #NeuroendocrineCancer #NETResearch #ClinicalTrials
-
-
📣We share with you the #Article "Novel Insights into Redox-Based Mechanisms for Auranofin-Induced Rapid Cancer Cell Death" 🧐by Elie Hatem, et al. Université Paris-Saclay Access the full paper here▶️ https://lnkd.in/d4Afc5-A Keywords: auranofin; oxidative stress; redox regulation
-
